Exchange: NASDAQ·Updated 07:58 PM EDT
Upcoming Earnings:

Reports: Oct 29After Hours

Estimated EPS

$0.00

Estimated Rev

---

$FULC Q1 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.25 up 10.71% YoY • Fulcrum Therapeutics expects existing cash, cash equivalents, and marketable securities of $333.3 million as of March 31, 2026, to fund operating expenses and capital expenditures into 2029. The company also plans to provide next trial design details in Q2 2026.

Generated by Stocktwits using AI and company-reported earnings data. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.

Historical Earnings

Quarterly

Annual

EPS

Revenue

Fiscal PeriodEstimatedReportedSurpriseResult

Advertisement|Remove ads.